Risk of Neurological Adverse Events Between PD-L1 and PD-1 Inhibitors in South Korean Patients with Lung Cancer: A Target Trial Emulation Framework
Sang Hee Kim, Seung Hyeun Lee, Sukhyang Lee, Sun-Young Chang, Ha-Lim Jeon, Hankil Lee · 2026
Read Risk of Neurological Adverse Events Between PD-L1 and PD-1 Inhibitors in South Korean Patients with Lung Cancer: A Target Trial Emulation Framework by Sang Hee Kim, Seung Hyeun Lee, Sukhyang Lee, Sun-Young Chang, Ha-Lim Jeon, Hankil Lee (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13612710.txt.
Description
Sang Hee Kim and colleagues present a 2026 South Korean study comparing nerve-related side effects of two groups of cancer immunotherapy drugs in people with lung cancer. One group blocks a protein called PD-1, and the other blocks its partner, PD-L1. Such side effects are uncommon, yet they can be serious, so knowing whether one drug group carries more risk helps doctors choose and monitor treatment.
Using nationwide health data and a design that mimics a clinical trial, the team matched 931 patients in each group. Nerve problems in the limbs were more common with PD-L1 drugs overall, at 19.2 percent against 14.1 percent. Timing differed too: early problems within 30 days were more common with PD-1 drugs, while the pattern shifted after three months.
Catalog record
| CREATOR | Sang Hee Kim, Seung Hyeun Lee, Sukhyang Lee, Sun-Young Chang, Ha-Lim Jeon, Hankil Lee |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |